CNBC: Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June
Moderna’s Covid-19 vaccine is the second shot behind Pfizer’s to demonstrate high efficacy in younger age groups.
CNBC reports that this would “dramatically expand the number of shots available to middle and high school students ahead of the next school year.”
We just announced that the Phase 2/3 study of our COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint. In the study, no cases of COVID-19 were observed in participants who had received 2 doses of the vaccine: https://t.co/SHTokbDhKR pic.twitter.com/rqHEfmi9s9
— Moderna (@moderna_tx) May 25, 2021
